Miofilin (Aminophylline)

Aminophylline, the active ingredient in Miofilin, is a methylxanthine presented as an oral formulation for systemic use. It provides bronchodilation to manage asthma, chronic obstructive pulmonary disease (COPD) and bronchospasm in patients requiring respiratory support.

GNH USA supplies Miofilin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to facilitate import and distribution across multiple regions. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Miofilin (aminophylline) is a methylxanthine bronchodilator that works within the respiratory disease pathway to increase airway caliber and ease breathing difficulties. - Asthma: provides bronchodilation that improves airflow, reduces wheezing, and decreases the need for rescue inhalers in patients with reversible airway obstruction. - Chronic obstructive pulmonary disease (COPD): decreases airway resistance and alleviates dyspnea during stable disease and acute exacerbations, supporting better exercise tolerance in chronic obstructive pulmonary disease patients. - Bronchospasm: rapidly relaxes bronchial smooth muscle, restoring ventilation and relieving acute bronchospastic episodes caused by allergens, irritants, or infection.

Aminophylline may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: gastrointestinal discomfort that may include vomiting. - Headache: mild to moderate intensity. - Tremor: fine muscle tremors, especially in the hands. - Insomnia: difficulty falling or staying asleep. - Palpitations: sensation of rapid or irregular heartbeat. - Diarrhea: loose stools. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Cardiac arrhythmias: potentially life‑threatening irregular heart rhythms. - Seizures: convulsive episodes, particularly at high plasma concentrations. - Severe hypotension: marked drop in blood pressure causing dizziness. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing aminophylline, clinicians should observe several safety considerations to minimize risk. - Assess cardiac history: patients with known arrhythmias require careful monitoring. - Evaluate liver function: impaired metabolism can increase drug levels. - Monitor serum aminophylline concentrations: therapeutic drug monitoring helps avoid toxicity. - Caution in the elderly: age‑related sensitivity may increase adverse effects. - Avoid use in uncontrolled hypertension: may exacerbate blood pressure elevation. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Aminophylline interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluoroquinolones, cimetidine): may raise plasma aminophylline levels. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): increase risk of toxicity. - Concurrent theophylline products: additive effect leading to overdose. - Quinolone antibiotics (e.g., ciprofloxacin): potent inhibition of metabolism.

Moderate Interactions (Monitor Closely): - Beta‑agonists (e.g., albuterol): may augment tachycardia and tremor. - Diuretics (e.g., furosemide): can cause electrolyte disturbances enhancing side effects. - Corticosteroids (e.g., prednisone): may increase bronchodilator response, requiring dose adjustment. - Anticoagulants (e.g., warfarin): possible alteration of INR, monitor coagulation.